Product Pathways - Protein Stability
TRIM27 Antibody #12663
|12663S||100 µl (10 western blots)||---||In Stock||---|
|12663||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
|W||1:1000||Human, Mouse, Rat||Endogenous||58||Rabbit|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting
Species predicted to react based on 100% sequence homology: Monkey, Bovine.
Specificity / Sensitivity
TRIM27 Antibody recognizes endogenous levels of total TRIM27 protein. A background band is detected in some cell lines at 130 kDa.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu255 of human TRIM27 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Tripartite motif containing protein 27 (TRIM27, RFP) is a member of the tripartite motif (TRIM) family whose members contain a RING domain, a B-box, and a coiled-coil region (together called RBCC). TRIM27 was originally discovered as part of an oncogenic DNA rearrangement resulting in fusion of the amino terminal RBCC region of TRIM27 with the carboxyl terminal kinase domain of the receptor tyrosine kinase Ret (1). Overexpression of TRIM27 induces JNK and p38 MAPK activation as well as apoptosis (2). TRIM27 has been found to have pleiotropic effects including transcriptional repression (3,4), and E3 ligase activity for ubiquitin (5-7), and SUMO (8). TRIM27 was originally found to interact with Enhancer of Polycomb (EPC) and function as a transcriptional repressor (3). Subsequent studies have identified ubiquitin E3 ligase activity in TRIM27 as well as other members of the TRIM family (reviewed in 9). Potential substrates of TRIM27 mediated ubiquitination include class II PI3K-C2β, NOD2, and WASH. Elevated expression of TRIM27 has been observed in several cancer types of cancer, where in some cases it may be a predictor of poor prognosis (10-13).
- Takahashi, M. et al. (1988) Mol Cell Biol 8, 1853-6.
- Dho, S.H. and Kwon, K.S. (2003) J Biol Chem 278, 31902-8.
- Shimono, Y. et al. (2000) J Biol Chem 275, 39411-9.
- Bloor, A.J. et al. (2005) Oncogene 24, 6729-36.
- Cai, X. et al. (2011) Proc Natl Acad Sci U S A 108, 20072-7.
- Zurek, B. et al. (2012) PLoS One 7, e41255.
- Hao, Y.H. et al. (2013) Cell 152, 1051-64.
- Chu, Y. and Yang, X. (2011) Oncogene 30, 1108-16.
- Meroni, G. and Diez-Roux, G. (2005) Bioessays 27, 1147-57.
- Tezel, G.G. et al. (2009) Pathol Res Pract 205, 403-8.
- Tsukamoto, H. et al. (2009) Cancer Sci 100, 1895-901.
- Iwakoshi, A. et al. (2012) Pathol Int 62, 324-30.
- Zoumpoulidou, G. et al. (2012) J Natl Cancer Inst 104, 941-52.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.